GalleonBio is a mid-stage biopharmaceutical company focusing on the development of novel topical therapies for the management of inflammatory dermatological, neuropathic pain and other conditions. Based on multiple years of research and scientific innovation in rare earth metals, GalleonBio’s scientists have developed a unique therapeutic technology platform of products containing strontium. Based in the USA GalleonBio are implementing a worldwide clinical development program to support it’s patented advances reaching patients in multiple disease states globally. Alternative routes of administration to treat additional indications are also being tested.
Based on existing evidence, GB400 has the promise to be a unique product introduction with multiple therapeutic pathways. GB400 will be the only topical treatment with the potential to break the itch-scratch-inflammation-itch cycle. GB400 promises to be a valuable solution to the unmet needs in psoriasis management for patients, health care providers and payers.